Targeting gastrointestinal stromal tumors: The role of regorafenib

Brett Schroeder, Zula Li, Lee D. Cranmer, Robin L. Jones, Seth M. Pollack

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Gastrointestinal stromal tumor (GIST) is a devastating disease in the metastatic setting, but its natural history has been dramatically altered by the development of small molecule tyrosine kinase inhibitors, most notably imatinib. Although patients with advanced GIST live much longer today than they did in the past, imatinib-refractory disease remains a tremendous problem. For disease that is refractory to imatinib and sunitinib, regorafenib is an excellent option. In this review, we discuss the biology and clinical work establishing regorafenib as the standard of care for advanced GIST refractory to both imatinib and sunitinib.

Original languageEnglish (US)
Pages (from-to)3009-3016
Number of pages8
JournalOncoTargets and Therapy
StatePublished - May 20 2016
Externally publishedYes


  • GIST
  • Imatinib
  • Refractory
  • Regorafenib

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Targeting gastrointestinal stromal tumors: The role of regorafenib'. Together they form a unique fingerprint.

Cite this